ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Feinstein Institutes report on early mapping of vagus nerve, unveil novel stimulator for bioelectronic medicine research

Starting in the brain and extending to our organs, the vagus nerve helps communicate and maintain how the body functions, including heart rate, breathing and immune response. For the first time, researchers at The Feinstein Institutes for Medical Research are microscopically mapping more than 100,000 individual fibers that make up the vagus nerve to determine how they are anatomically connected and which bodily function it controls. Bioelectronic medicine scientists published their early mapping in the journal Brain Stimulation, along with a novel vagus nerve stimulator that can activate targeted fibers, opening up new avenues of vagus nerve stimulation (VNS) research.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230224005280/en/

Stavros Zanos, MD, PhD, is senior author on the research, which published in the journal Brain Stimulation. (Credit: Feinstein Institutes)

Stavros Zanos, MD, PhD, is senior author on the research, which published in the journal Brain Stimulation. (Credit: Feinstein Institutes)

The study, led by Stavros Zanos, MD, PhD, associate professor at the Feinstein Institutes’ Institute of Bioelectronic Medicine, deployed advanced methods for surgical dissection, imaging and microscopic anatomy to map how vagal fibers are organized inside the vagus nerve in animal models. The team found fibers that connect to the larynx, lung and heart lie in different parts of the nerve. They also discovered that sensory and motor fibers are in separate locations, which are close to the neck and later disappear as the nerve enters the chest cavity.

“To advance the field of bioelectronic medicine and effectiveness of vagus nerve stimulation therapies, we must first understand what part of the nerve we are stimulating and what that does to the body,” said Dr. Zanos, senior author of the paper. “Through our early mapping and new electrical stimulation vagal nerve cuff, we hope to unlock the potential of VNS to treat more effectively organ-specific diseases.”

The team’s animal model VNS cuff wraps around the vagus nerve and has 10 contacts instead of the standard two contacts used today in clinical VNS devices. By electrically stimulating individual contacts around the nerve, the group showed that nerve fibers can be more selectively activated. For example, by stimulating the contact that lies away from nerve fibers to the larynx and closer to nerve fibers to the lung, they were able to affect lung function with a smaller impact on laryngeal function.

The cuff’s effectiveness shows the ability to hone in and select fibers to a single organ of interest while avoiding others. Existing VNS therapies cannot easily target the nerves that engage a specific organ (i.e. the heart in atrial fibrillation or the lungs in pulmonary hypertension). Frequently, existing VNS therapies produce side effects from non-targeted organs, like voice changes, throat pain and coughing. Even though those effects are not life-threatening, a more selective, targeted approach to VNS could potentially reduce those side effects and use VNS to treat organ-specific diseases better.

“Despite the importance of the vagus nerve and wide interest in methods to stimulate it, the basic anatomy of this nerve is largely unknown,” said Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes and Karches Family Distinguished Chair in Medical Research. “Dr. Zanos’ current study provides a new basic foundation for understanding vagus nerve function and structure.”

This current research aided in Dr. Zanos and the Feinstein Institutes securing a $6.7 million grant from the National Institutes of Health (NIH). The award will help Dr. Zanos and his lab create a detailed map of the anatomy of the human vagus nerve. The funding is part of the NIH Common Fund’s Stimulating Peripheral Activity to Relieve Conditions program.

The Feinstein Institutes for Medical Research is the global scientific home of bioelectronic medicine, which combines molecular medicine, neuroscience and biomedical engineering. At the Feinstein Institutes, medical researchers use modern technology to develop new device-based therapies to treat disease and injury.

Built on years of research in molecular mechanisms of disease and the link between the nervous and immune systems, our researchers discover neural targets that can be activated or inhibited with neuromodulation devices, like vagus nerve implants, to control the body’s immune response and inflammation. If inflammation is successfully controlled, diseases – such as arthritis, pulmonary hypertension, Crohn’s disease, inflammatory bowel diseases, diabetes, cancer and autoimmune diseases – can be treated more effectively. Beyond inflammation, using novel brain-computer interfaces, our researchers developed techniques to bypass injuries of the nervous system so that people living with paralysis can regain sensation and use their limbs. By producing bioelectronic medicine knowledge, disease and injury could one day be treated with our own nerves without costly and potentially harmful pharmaceuticals.

About the Feinstein Institutes

The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State. Encompassing 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health system science, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine. For more information about how we produce knowledge to cure disease, visit http://feinstein.northwell.edu and follow us on LinkedIn.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  222.56
+0.02 (0.01%)
AAPL  274.61
+0.50 (0.18%)
AMD  209.17
+1.59 (0.77%)
BAC  54.81
-0.52 (-0.94%)
GOOG  307.73
-1.59 (-0.51%)
META  657.15
+9.64 (1.49%)
MSFT  476.39
+1.57 (0.33%)
NVDA  177.72
+1.43 (0.81%)
ORCL  188.65
+3.73 (2.02%)
TSLA  489.88
+14.57 (3.07%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.